Protein Summary
May function in the control of the neuroendocrine secretory pathway. Proposed be a specific endogenous inhibitor of PCSK1. ProSAAS and Big PEN-LEN, both containing the C-terminal inhibitory domain, but not the further processed peptides reduce PCSK1 activity in the endoplasmic reticulum and Golgi. It reduces the activity of the 84 kDa form but not the autocatalytically derived 66 kDa form of PCSK1. Subsequent processing of proSAAS may eliminate the inhibition. Slows down convertase-mediated processing of proopiomelanocortin and proenkephalin. May control the intracellular timing of PCSK1 rather than its total level of activity. The function of the processed secreted peptides is not known (By similarity). The protein encoded by this gene functions as an inhibitor of prohormone convertase 1, which regulates the proteolytic cleavage of neuroendocrine peptide precursors. The proprotein is further processed into multiple short peptides. A polymorphism within this gene may be associated with ...more
- ENST00000218230
- ENSP00000218230
- ENSG00000102109
- PEN
- SAAS
- SCG8
- BigLEN
- SgVIII
- PROSAAS
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
gene perturbation | 0.9 | ||
cellular component | 0.68 | ||
PubMedID | 0.55 | ||
biological process | 0.51 | ||
cell type or tissue | 0.5 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 57.76 (req: < 5)
Gene RIFs: 5 (req: <= 3)
Antibodies: 91 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 57.76 (req: >= 5)
Gene RIFs: 5 (req: > 3)
Antibodies: 91 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 7
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0